🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,265 results for “Gan” Clear

  1. osimertinib mesylate tablets and anlotinib hydrochloride capsules

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  2. pembrolizumab

    The First People's Hospital of Lianyungang

    Advanced Non-squamous Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  3. penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

    The First People's Hospital of Lianyungang

    Lymphoma, Large B-Cell, Diffuse

    phase 2 small molecule active

    1 trial

  4. pharmorubicin or pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  5. placebo

    The First People's Hospital of Lianyungang

    COVID-19 Thalidomide

    phase 2 small molecule active

    1 trial

  6. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    The First People's Hospital of Lianyungang

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  7. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  8. retinal pigment epithelium transplantation

    The First People's Hospital of Lianyungang

    Dry Age-related Macular Degeneration

    phase 2 mab active

    1 trial

  9. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial

  10. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

  11. sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  12. ssCART-19

    The First People's Hospital of Lianyungang

    Relapsed or Refractory Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  13. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

  14. surufatinib + fulvestrant + chidamide

    The First People's Hospital of Lianyungang

    Breast Cancer

    phase 2 small molecule active

    1 trial

  15. tauroursodeoxycholic acid (TUDCA)

    The First People's Hospital of Lianyungang

    Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development

    phase 2 small molecule active

    1 trial

  16. toripalimab

    The First People's Hospital of Lianyungang

    Malignant Melanoma

    phase 2 small molecule active

    1 trial

  17. trifluridine/tipiracil combined with fufuquitinib

    The First People's Hospital of Lianyungang

    Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  18. unrelated umbilical cord blood

    The First People's Hospital of Lianyungang

    Myelodysplastic Syndromes

    phase 2 small molecule active

    1 trial

  19. veneclax, chidaniline combined with azacitidine (VCA) followed by decitabine + MAG regimen (D-MAG)

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  20. zigakibart

    Novartis Pharmaceuticals

    Immunoglobulin A Nephropathy (IgAN)

    phase 2 mab active

    1 trial

  21. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  22. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 small molecule active

    1 trial

  23. 68Ga-AAZTA-NI-093

    The First People's Hospital of Lianyungang

    Prostate Cancer (Adenocarcinoma)

    phase 1 small molecule active

    1 trial

  24. 68Ga-BNU-PSMA

    The First People's Hospital of Lianyungang

    Tumor

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources